December 7, 2017

NanoString Technologies Highlights Advances in Precision Oncology at the 59th Annual Meeting of the American Society of Hematology

More than 45 Abstracts Highlight the Value of the nCounter Platform in Hematology, including 11 that Demonstrate the Potential Clinical Utility of the Lymphoma Subtyping Test

Company Announces Launch of Vantage 3D DNA:RNA:Protein Hematology Assays

SEATTLE, Dec. 07, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial availability of new Vantage 3D™ Hematology assays as well as the highlights of more than 45 nCounter®-based research abstracts that will be presented at the 59th Annual Meeting of the America Society of Hematology being held December 9-12, in Atlanta.

The company announced the launch of new Vantage 3D hematology assays. Three of the studies presented at ASH (Abstracts 1758, 2481 and 3945) include data from early access versions of NanoString's Vantage 3D DNA:RNA:Protein Heme Assays, which are launching commercially at ASH. These assays enable simultaneous, multi-analyte analysis of single nucleotide variants (SNVs), RNA, protein, and phospho-protein. The assay includes curated content that covers clinically actionable SNVs and Indels, and provide comprehensive expression profiling of RNA, protein, and phospho-protein in key pathways including PI3K, JAK-STAT, BCR, and TCR signaling.

One of the presentations will be made by Dr. Sergio Rutella, M.D. Ph.D. FRCPath., Professor of Cancer Immunotherapy at the John van Geest Cancer Research Centre at Nottingham Trent University. Dr. Rutella stated, "AML is a rare disease and we need to maximize the amount of information we collect. We are using NanoString's Vantage 3D DNA:RNA:Protein Heme Assay to capture information about single nucleotide variants, mutations, and new antigens that could be compiled into a 'super signature' to better characterize the disease and stratify the treatment of patients."

"Our customers and collaborators are presenting a record body of nCounter-based research at the 59th annual ASH conference," said Brad Gray, president and chief executive officer of NanoString Technologies. "This research demonstrates the advances that are being enabled with the nCounter platform in subtyping lymphomas and optimizing regimens to achieve better clinical outcomes."

The ASH Annual Meeting will include at least four oral presentations and forty-one posters in various leukemia, lymphoma, and myeloma malignancies that demonstrate the utility of the nCounter platform across the heme-oncology spectrum. In particular, NanoString's collaborators in Diffuse Large B-Cell Lymphoma (DLBCL) are presenting 11 abstracts highlighting the potential clinical relevance of NanoString's Lymphoma Subtyping Test (LST) and its potential for directing treatment decisions, including:

- Results from the frontline prospective Phase III BIO-DLBCL04 study conducted by the Fondazione Italiana Linfomi (FIL). The results show that ABC subtype determined by the NanoString LST assay is associated with a worse outcome in untreated, poor-risk, young DLBCL (Abstract #4010).

- Researchers from the European Institute of Oncology found that the NanoString LST robustly identifies DLBCL subgroups according to the Cell-of-Origin (COO). The molecular definition of the COO can be used to identify patients at high risk of poor outcome when treated with R-CHOP and who may benefit by intensified high dose chemotherapy or experimental new treatments (Abstract #3998).

- Results from an exploratory biomarker analysis of the Phase 3 GOYA Trial comparing the efficacy and safety of obinutuzumab plus CHOP (G-CHOP) with R-CHOP in patients with previously untreated DLBCL. Using the NanoString LST assay and a new cutoff on the Linear Predictor Score (LPS), a new distinct molecular subgroup of GCB DLBCL, referred to as "strong-GCB", was identified. Results from the exploratory analysis show that treatment with G-CHOP confers substantial clinical benefit over R-CHOP in this new subgroup of DLBCL (Abstract #1543).

The table below includes a selection of 2017 ASH abstracts that best illustrate the potential clinical utility of nCounter across multiple tumor types. You can learn more about the capabilities of the nCounter platform by visiting NanoString at booth #2465 at ASH.

Abstract #	Title	Hyperlink
1543	Superiority of Obinutuzumab over Rituximab in a New Molecular Follicular Lymphoma-like Subgroup of DLBCL: Results from an Exploratory Analysis of the Phase 3 GOYA Trial	https://ash.confex.com/ash/2017/webprogram/Paper106657.html
2729	Systematic Analysis of the Prognostic Impact of Somatic Mutations in Diffuse Large B-Cell Lymphoma (DLBCL) with Evaluation of Cell-of-Origin Dependence: Results from the Phase 3 GOYA Trial in Previously Untreated DLBCL	https://ash.confex.com/ash/2017/webprogram/Paper105237.html
4010	ABC Subtype, TP53 Mutation and BCL2 Overexpression Are Associated with a Worse Outcome in Untreated Poor-Risk Young Diffuse Large B-Cell Lymphoma: Results from the Frontline Phase III BIO-DLBCL04 Study of the Fondazione Italiana Linfomi	https://ash.confex.com/ash/2017/webprogram/Paper108156.html
2745	Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or NanoString Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients	https://ash.confex.com/ash/2017/webprogram/Paper105158.html
4009	Cell of Origin and Genomic Profile of Primary Central Nervous System Lymphoma Determined Using the NanoString LST Assay and Ultra Deep Targeted Next Generation Sequencing	https://ash.confex.com/ash/2017/webprogram/Paper106405.html
1758	Simultaneous Detection of Single Nucleotide Variants and Expression of RNA and Protein in Multiple Myeloma Bone Marrow Aspirates	https://ash.confex.com/ash/2017/webprogram/Paper105946.html
1196	Spatially Resolved, Multiplexed Digital Characterization of Protein Distribution and Abundance in Formalin-Fixed, Paraffin-Embedded (FFPE) Diffuse Large B Cell Lymphoma Tissue Sections Based on the NanoString® Digital Spatial (DSP) Technology	https://ash.confex.com/ash/2017/webprogram/Paper106084.html
2481	An Assay for Simultaneous Profiling of Gene Expression, Phospho- and Total Protein Abundance, and Somatic DNA Mutations for Hematology-Oncology Research	https://ash.confex.com/ash/2017/webprogram/Paper107651.html
3942	Immune Gene Expression Profiling in Children and Adults with Acute Myeloid Leukemia Identifies Distinct Phenotypic Patterns	https://ash.confex.com/ash/2017/webprogram/Paper99659.html
3945	Interferon-γ Induces Distinct mRNA and Protein Profiles in Acute and Chronic Myeloid Leukemia	https://ash.confex.com/ash/2017/webprogram/Paper100765.html
195	High Expression of Programmed Death-Ligand 1 (PD-L1) Correlates with Macrophage Gene Expression and Is Associated with Prolonged Progression-Free Survival (PFS) in Patients (pts) with First-Line (1L) Diffuse Large B-Cell Lymphoma (DLBCL)	https://ash.confex.com/ash/2017/webprogram/Paper105749.html
190	Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial	https://ash.confex.com/ash/2017/webprogram/Paper100623.html
1551	CC-122 DLBCL-001: Phase Ib Study of CC-122 Plus Rituximab in Patients with Chemo-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	https://ash.confex.com/ash/2017/webprogram/Paper102089.html
418	BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL	https://ash.confex.com/ash/2017/webprogram/Paper105778.html
727	Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials	https://ash.confex.com/ash/2017/webprogram/Paper105440.html
3998	Molecular Definition of Activated B Cell-like (ABC) DLBCL Identifies Patients Who May Benefit from Front-Line Intensive R-HDS Chemotherapy with ASCT	https://ash.confex.com/ash/2017/webprogram/Paper105025.html
4118	A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC-122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B-Cell Lymphoma Subjects: Results from the Phase I CC-122-ST-001 Study	https://ash.confex.com/ash/2017/webprogram/Paper102096.html

About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The

company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,800 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

Vantage 3D™ Hematology assays are for research use only and not for use with diagnostic procedures.

For more information, please visit www.nanostring.com.

Contact:

Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768

Primary Logo

Source: NanoString Technologies, Inc.

News Provided by Acquire Media